Impact of Chemotherapy on the Mobilisation, Harvest and Economic Costs of Autologous Peripheral Stem Cell Transplantation in Patients with Multiple Myeloma

References

• Thomas E. D., Epstein R. B. Bone marrow transplantation in acute leukemia. Cancer Res 1965; 25: 1521–1524
   PubMed Web of Science ®Google Scholar
• Attal M., Harousseau J. L. Standard therapy versus autologous transplantation in multiple myeloma. Hematol Oncol Clin North Am 1997; 11: 133–146
   PubMed Web of Science ®Google Scholar
• Trippoli S., Messori A., Becagli P., et al. Treatments for newly diagnosed multiple myeloma: analysis of survival data and cost‐effectiveness evaluation. Oncol Rep 1998; 5: 1475–1482
   PubMed Web of Science ®Google Scholar
• Harousseau J. L., Attal M. The role of autologous hematopoietic stem cell transplantation in multiple myeloma. Semin Hematol 1997; 34: 61–66
   PubMed Web of Science ®Google Scholar
• Bensinger W. I., Rowley S. D., Demirer T., et al. High‐dose therapy followed by autologous hematopoietic stem‐cell infusion for patients with multiple myeloma. J Clin Oncol 1996; 14: 1447–1456
   PubMed Web of Science ®Google Scholar
• Alegre A., Lamana M., Arranz R., et al. Busulfan and melphalan as conditioning regimen for autologous peripheral blood stem cell transplantation in multiple myeloma. Br J Haematol 1995; 91: 380–386
   PubMed Web of Science ®Google Scholar
• Tricot G., Jagannath S., Vesole D. H., et al. Hematopoietic stem cell transplants for multiple myeloma. Leuk Lymphoma 1996; 22: 25–36
   PubMed Web of Science ®Google Scholar
• Gianni A. M., Siena S., Bregni M., et al. Granulocyte‐macrophage colony‐stimulating factor to harvest circulating haemopoietic stem cells for autotransplantation. Lancet 1989; 2: 580–585
   PubMed Web of Science ®Google Scholar
• Jerjis S., Croockewit S., Muus P., et al. Cost analysis of autologous peripheral stem cell transplantation versus autologous bone marrow transplantation for patients with non Hodgkin's lymphoma and acute lymphocytic leukaemia. Leuk Lymphoma 1999, in press
   PubMed Web of Science ®Google Scholar
• Henon P. R., Liang H., Beck Wirth G., et al. Comparison of hematopoietic and immune recovery after autologous bone marrow or blood stem cell transplants. Bone Marrow Transplant 1992; 9: 285–291
   PubMed Web of Science ®Google Scholar
• Schmitz N., Linch D. C., Dreger P., et al. Randomised trial of filgrastim‐mobilised peripheral blood progenitor cell transplantation versus autologous bone‐marrow transplantation in lymphoma patients. Lancet 1996; 347: 353–357
   PubMed Web of Science ®Google Scholar
• Sheridan W. P., Begley C. G., Juttner C. A., et al. Effect of peripheral‐blood progenitor cells mobilised by filgrastim (G‐CSF) on platelet recovery after high‐dose chemotherapy. Lancet 1992; 339: 640–644
   PubMed Web of Science ®Google Scholar
• Smith T. J., Hillner B. E., Schmitz N., et al. Economic analysis of a randomized clinical trial to compare filgrastim‐mobilized peripheral‐blood progenitor‐cell transplantation and autologous bone marrow transplantation in patients with Hodgkin's and non‐Hodgkin's lymphoma. J Clin Oncol 1997; 15: 5–10
   PubMed Web of Science ®Google Scholar
• To L. B., Roberts M. M., Haylock D. N., et al. Comparison of haematological recovery times and supportive care requirements of autologous recovery phase peripheral blood stem cell transplants, autologous bone marrow transplants and allogeneic bone marrow transplants. Bone Marrow Transplant 1992; 9: 277–284
   PubMed Web of Science ®Google Scholar
• Schmitz N., Linch D. C., Dreger P., et al. Randomised trial of filgrastim‐mobilised peripheral blood progenitor cell transplantation versus autologous bone‐marrow transplantation in lymphoma patients. Loncet 1996; 347: 353–357
   PubMed Web of Science ®Google Scholar
• Bennett C. L., Armitage J. L., Armitage G. O., et al. Costs of care and outcomes for high‐dose therapy and autologous transplantation for lymphoid malignancies: results from the University of Nebraska 1987 through 1991. J Clin Oncol 1995; 13: 969–973
   PubMed Web of Science ®Google Scholar
• Julia A., Bueno J., Gadea N., et al. [Economic study of the cost of peripheral blood hematopoietic precursor autotransplantation compared with bone marrow transplantation]. Med Clin Barc 1995; 105: 131–135
   PubMed Web of Science ®Google Scholar
• Rio B., Marjanovic Z., Belhocine R., et al. [Difference in costs of autologous transplantation of peripheral and bone marrow hematopoietic stem cells. A retrospective analysis over 1 year of transplantation in lymphoma, Hodgkin's disease and myeloma in a Center] Difference de cout des autogreffes de cellules‐souches hematopoietiques circulantes et medullaires. Ann Med Interne Paris 1996; 147: 313–319
   PubMedGoogle Scholar
• Ager S., Scott M. A., Mahendra P., et al. Peripheral blood stem cell transplantation after high‐dose therapy in patients with malignant lymphoma: a retrospective comparison with autologous bone marrow transplantation. Bone Marrow Transplant 1995; 16: 79–83
   PubMed Web of Science ®Google Scholar
• de Groot Uyl, Richel D. J., Rutten E. F. Peripheral blood progenitor cell transplantation mobilised by r‐metHuG‐CSF (filgrastim); a less costly alternative to autologous bone marrow transplantation. Eur J Cancer 1994; 11: 1631–1635
   Google Scholar
• Meisenberg B. R., Miller W. E., McMillan R., et al. Outpatient high‐dose chemotherapy with autologous stem‐cell rescue for hematologic and nonhematologic malignancies. J Clin Oncol 1997; 15: 11–17
   PubMed Web of Science ®Google Scholar
• Bender J. G., To L. B., Williams S., et al. Defining a therapeutic dose of peripheral blood stem cells. J Hematother 1992; 1: 329–341
   PubMedGoogle Scholar
• Gaspard M. H., Maraninchi D., Stoppa A. M., et al. Intensive chemotherapy with high doses of BCNU, etoposide, cytosine arabinoside, and melphalan (BEAM) followed by autologous bone marrow transplantation: toxicity and antitumor activity in 26 patients with poor‐risk malignancies. Cancer Chemother Pharmacol 1988; 22: 256–262
   PubMed Web of Science ®Google Scholar
• Mahendra P., Johnson D., Scott M. A., et al. Peripheral blood progenitor cell transplantation: a single centre experience comparing two mobilisation regimens in 67 patients. Bone Marrow Transplant 1996; 17: 503–507
   PubMed Web of Science ®Google Scholar
• Martino M., Morabito F., Messina G., et al. Fractionated infusions of cryopreserved stem cells may prevent DMSO‐induced major cardiac complications in graft recipients. Haematologica 1996; 81: 59–61
   PubMed Web of Science ®Google Scholar
• Kiss J. E., Rybka W. B., Winkelstein A., et al. Relationship of CD34+ cell dose to early and late hematopoiesis following autologous peripheral blood stem cell transplantation. Bone Marrow Transplant 1997; 19: 303–310
   PubMed Web of Science ®Google Scholar
• Bensinger W. I., Longin K., Appelbaum F., et al. Peripheral blood stem cells (PBSCs) collected after recombinant granulocyte colony stimulating factor (rhG‐CSF): an analysis of factors correlating with the tempo of engraftment after transplantation [see comments]. Br J Haematol 1994; 87: 825–831
   PubMed Web of Science ®Google Scholar
• Weaver C. H., Hazelton B., Birch R., et al. An analysis of engraftment kinetics as a function of the CD34 content of peripheral blood progenitor cell collections in 692 patients after the administration of myeloablative chemotherapy. Blood 1995; 86: 3961–3969
   PubMed Web of Science ®Google Scholar
• Dreger P., Kloss M., Petersen B., et al. Autologous progenitor cell transplantation: prior exposure to stem cell‐toxic drugs determines yield and engraftment of peripheral blood progenitor cell but not of bone marrow grafts. Blood 1995; 86: 3970–3978
   PubMed Web of Science ®Google Scholar
• Okunewick J. P., Buffo M. J., Kociban D. L. Comparative toxicity of mitoxantrone and doxorubicin on hematopoietic stem cells. Exp Hematol 1985; 13(Suppl. 16)23–30
   PubMed Web of Science ®Google Scholar
• Haas R., Mohle R., Fruhauf S., et al. Patient characteristics associated with successful mobilizing and autografting of peripheral blood progenitor cells in malignant lymphoma. Blood 1994; 83: 3787–3794
   PubMed Web of Science ®Google Scholar
• Moskowitz C. H., Glassman J. R., Wuest D., et al. Factors affecting mobilization of peripheral blood progenitor cells in patients with lymphoma. Clin Cancer Res 1998; 4: 311–316
   PubMed Web of Science ®Google Scholar
• Dune B. G., Salmon S. E. A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival. Cancer 1975; 36: 842–854
   PubMed Web of Science ®Google Scholar
• Marit G., Faberes C., Pico J. L., et al. Autologous peripheral‐blood progenitor‐cell support following high‐dosechemotherapy or chemoradiotherapy in patients with high‐risk multiple myeloma. J Clin Oncol 1996; 14: 1306–1313
   PubMed Web of Science ®Google Scholar
• Valls A., Ferrer E., Algara M., et al. Fractionated total body irradiation for bone marrow transplantation: clinical results on 66 patients. Radiother. Oncol 1990; 18(Suppl. 1)151–154
   PubMedGoogle Scholar
• Bensinger W. I., Rowley S. D., Demirer T., et al. High‐dose therapy followed by autologous hematopoietic stem‐cell infusion for patients with multiple myeloma. J Clin Oncol 1996; 14: 1447–1456
   PubMed Web of Science ®Google Scholar
• Bensinger W., Appelbaum F., Rowley S., et al. Factors that influence collection and engraftment of autologous peripheral‐blood stem cells. J Clin Oncol 1995; 13: 2547–2555
   PubMed Web of Science ®Google Scholar
• Kotasek D., Shepherd K. M., Sage R. E., et al. Factors affecting blood stem cell collections following high‐dose cyclophosphamide mobilization in lymphoma, myeloma and solid tumors. Bone Marrow Transplant 1992; 9: 11–17
   PubMed Web of Science ®Google Scholar
• Moskowitz C. H., Stiff P., Gordon M. S., et al. Recombinant methionyl human stem cell factor and filgrastim for peripheral blood progenitor cell mobilization and transplantation in non‐Hodgkin's lymphoma patients‐results of a phase I/II trial. Blood 1997; 89: 3136–3147
   PubMed Web of Science ®Google Scholar
• Glaspy J. A., Shpall E. J., LeMaistre C. F., et al. Peripheral blood progenitor cell mobilization using stem cell factor in combination with filgrastim in breast cancer patients. Blood 1997; 90: 2939–2951
   PubMed Web of Science ®Google Scholar
• Bjorkstrand B. Multiple myeloma, high‐dose treatment and autologous stem cell transplantation‐current status. Med Oncol 1996; 13: 23–30
   PubMed Web of Science ®Google Scholar